胃肠病学
接收机工作特性
置信区间
医学
胰腺炎
内科学
川地163
单核细胞
曲线下面积
发病机制
免疫学
病理
巨噬细胞
化学
生物化学
体外
作者
Rasmus Hagn-Meincke,Srdan Novovic,Amer Hadi,Annette Bøjer Jensen,Asbjørn Mohr Drewes,Henrik Kraup,Jens Brøndum Frøkjær,Walter G. Park,Peter Leth Jørgensen,Holger Jon Møller,Bent Deleuran,Søren Schou Olesen
出处
期刊:Pancreas
[Ovid Technologies (Wolters Kluwer)]
日期:2024-12-02
标识
DOI:10.1097/mpa.0000000000002443
摘要
Abstract Objectives Activation of type M2 macrophages has been implicated in the pathogenesis of chronic pancreatitis (CP). In a clinical pilot study, we investigated blood-based markers of macrophage activation at different stages of CP. Methods We performed a cross-sectional analysis of prospectively collected plasma samples from healthy controls and patients with suspected or definitive CP according to the M-ANNHEIM criteria. Plasma concentrations of soluble CD163 (sCD163), soluble CD206 (sCD206), and monocyte chemoattractant protein-1 (MCP-1) were analyzed using enzyme-linked immunosorbent assays. Group and pairwise comparisons of analytes were performed using regression models and area under the receiver operating curves (AUC-ROC). Results In total, 73 subjects with CP (28 suspected CP and 45 definitive CP) and 40 controls were included. Compared to controls, the median plasma concentrations of sCD163 (p = 0.019) and sCD206 (p = 0.033) were elevated in patients with definitive CP. sCD206 was also elevated in patients with definitive CP (p = 0.042). ROC analysis revealed that the optimal sCD163 cutpoint to distinguish definitive CP from controls was 1.84 mg/ml (AUC-ROC 0.65; 95 % confidence interval [CI], 0.54-0.77). The optimal sCD206 cutpoint to distinguish definitive CP from controls was 0.24 mg/ml (AUC-ROC 0.66; 95 % CI 0.54-0.78). The analytes did not significantly discriminate patients with suspected CP from controls. MCP-1 concentrations showed no differences across subgroups. Conclusion Our study demonstrates that subjects with definitive CP, sampled during a clinically quiescent phase, exhibited increased levels of sCD163 and sCD206. This indicates the presence of activated M2 macrophages in patients with CP at advanced, but not early, clinical stages.
科研通智能强力驱动
Strongly Powered by AbleSci AI